Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism

Biochimica et Biophysica Acta - Biomembranes

Volumn 1768, Issue 4, 2007, Pages 923-940

  Meyer zu Heringdorf, Dagmar ^a   Jakobs, Karl H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Autotaxin; G protein coupled receptor; Lysophosphatidic acid; Lysophospholipid; Sphingosine kinase; Sphingosine 1 phosphate

Indexed keywords

CALCIUM ION; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; LYSOPHOSPHOLIPID RECEPTOR; PROTEIN G2A; PROTEIN GPR4; PROTEIN OGR1; PROTEIN TDAG68; PROTON; PSYCHOSINE; RECEPTOR PROTEIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 2; SPHINGOSYLPHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

CALCIUM HOMEOSTASIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETON; HUMAN; MULTIGENE FAMILY; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE; HUMANS; LYSOPHOSPHOLIPIDS; RECEPTORS, LYSOPHOSPHOLIPID; SIGNAL TRANSDUCTION;

EID: 33947427567     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.09.026     Document Type: Review

References (228)

1. Lefkowitz R.J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25 (2004) 413-422
2. Chun J., Goetzl E.J., Hla T., Igarashi Y., Lynch K.R., Moolenaar W.H., Pyne S., and Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54 (2002) 265-269
3. Howlett A.C. A short guide to the nomenclature of seven-transmembrane spanning receptors for lipid mediators. Life Sci. 77 (2005) 1522-1530
4. Anliker B., and Chun J. Lysophospholipid G protein-coupled receptors. J. Biol. Chem. 279 (2004) 20555-20558
5. Anliker B., and Chun J. Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol. 15 (2004) 457-465
6. Ishii I., Fukushima N., Ye X., and Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73 (2004) 321-354
7. Rosen H., and Goetzl E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev., Immunol. 5 (2005) 560-570
8. Gardell S.E., Dubin A.E., and Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 12 (2006) 65-75
9. Uhlenbrock K., Gassenhuber H., and Kostenis E. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell. Signal. 14 (2002) 941-953
10. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the EDG family. J. Biol. Chem. 278 (2003) 25600-25606
11. 5. J. Biol. Chem. (2006) M603670200
12. Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim. Biophys. Acta 1582 (2002) 81-88
13. Im D.S. Two ligands for a GPCR, proton vs lysolipid. Acta Pharmacol. Sin. 26 (2005) 1435-1441
14. Tomura H., Mogi C., Sato K., and Okajima F. Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cell. Signal. 17 (2005) 1466-1476
15. Tigyi G. Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins Other Lipid Mediators 64 (2001) 47-62
16. Spiegel S., English D., and Milstien S. Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol. 12 (2002) 236-242
17. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev., Cancer 3 (2003) 582-591
18. Spiegel S., and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev., Mol. Cell Biol. 4 (2003) 397-407
19. Rosen H. Chemical approaches to the lysophospholipid receptors. Prostaglandins Other Lipid Mediators 77 (2005) 179-184
20. Chun J., and Rosen H. Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr. Pharm. Des. 12 (2006) 161-171
21. Brinkmann V., Cyster J.G., and Hla T. FTY720: sphingosine-1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transp. 4 (2004) 1019-1025
22. Hecht J.H., Weiner J.A., Post S.R., and Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135 (1996) 1071-1083
23. Hla T., and Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G protein-coupled receptors. J. Biol. Chem. 265 (1990) 9308-9313
24. Lee M.-J., van Brocklyn J.R., Thangada S., Liu C.H., Hand A.R., Menzeleev R., Spiegel S., and Hla T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279 (1998) 1552-1555
25. 2+ mobilization, ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J. Biol. Chem. 273 (1998) 27104-27110
26. Zondag G.C.M., Postma F.R., van Etten I., Verlaan I., and Moolenaar W.H. Sphingosine-1-phosphate signalling through the G protein-coupled receptor EDG-1. Biochem. J. 330 (1998) 605-609
27. Radeff-Huang J., Seasholtz T.M., Matteo R.G., and Brown J.H. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J. Cell. Biochem. 92 (2004) 949-966
28. Sanchez T., and Hla T. Structural and functional characteristics of S1P receptors. J. Cell. Biochem. 92 (2004) 913-922
29. Taha T.A., Argraves K.M., and Obeid L.M. Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim. Biophys. Acta 1682 (2004) 48-55
30. Liu C.H., Thangada S., Lee M.-J., Van Brocklyn J.R., Spiegel S., and Hla T. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol. Biol. Cell 10 (1999) 1179-1190
31. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., and Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
32. i pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol. Cell. Biol. 23 (2003) 1534-1545
33. 2 G protein-coupled receptor. Requirement of inhibition of cellular Rac activity. J. Biol. Chem. 278 (2003) 32841-32851
34. 3. J. Clin. Invest. 113 (2004) 569-581
35. K.ACh by sphingosine-1-phosphate in human atrial cardiomyocytes. Mol. Pharmacol. 58 (2000) 449-454
36. Forrest M., Sun S.Y., Hajdu R., Bergstrom J., Card D., Doherty G., Hale J., Keohane C., Meyers C., Milligan J., Mills S., Nomura N., Rosen H., Rosenbach M., Shei G.J., Singer I.I., Tian M., West S., White V., Xie J., Proia R.L., and Mandala S. Immune cell regulation and cardiovascular effects of sphingosine-1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 309 (2004) 758-768
37. 3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279 (2004) 13839-13848
38. Ishii I., Friedman B., Ye X., Kawamura S., McGiffert C., Contos J.J., Kingsbury M.A., Zhang G., Brown J.H., and Chun J. Selective loss of sphingosine-1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J. Biol. Chem. 276 (2001) 33697-33704
39. 3/LP(B3)/EDG-3. J. Biol. Chem. 277 (2002) 25152-25159
40. Gräler M.H., Bernhardt G., and Lipp M. EDG-6, a novel G protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics 53 (1998) 164-169
41. 4 within the endothelial differentiation gene family of receptors. Biochem. J. 389 (2005) 187-195
42. 4/EDG-6 receptor. Biochem. Biophys. Res. Commun. 297 (2002) 600-606
43. 3H]-dihydrosphingosine-1-phosphate. Br. J. Pharmacol. 142 (2004) 851-860
44. 12/13. J. Cell. Biochem. 89 (2003) 507-519
45. van Brocklyn J.R., Gräler M.H., Bernhardt G., Hobson J.P., Lipp M., and Spiegel S. Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood 95 (2000) 2624-2629
46. 2+ signaling pathway. Biochem. Biophys. Res. Commun. 268 (2000) 583-589
47. 4-expressing cells. Genes Cells 8 (2003) 685-697
48. 4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 19 (2005) 1731-1733
49. Gräler M.H., and Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine-1-phosphate G-protein-coupled receptors. FASEB J. 18 (2004) 551-553
50. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
51. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., and Lynch K.R. The immune modulator FTY720 targets sphingosine-1-phosphate receptors. J. Biol. Chem. 277 (2002) 21453-21457
52. Glickman M., Malek R.L., Kwitek-Black A.E., Jacob H.J., and Lee N.H. Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein-coupled receptor, nrg-1. Mol. Cell. Neurosci. 14 (1999) 141-152
53. Malek R.L., Toman R.E., Edsall L.C., Wong S., Chiu J., Letterle C.A., van Brocklyn J.R., Milstien S., Spiegel S., and Lee N.H. Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. J. Biol. Chem. 276 (2001) 5692-5699
54. Im D.-S., Heise C.E., Ancellin N., O'Dowd B.F., Shei G., Heavens R.P., Rigby M.R., Hla T., Mandala S., McAllister G., George S.R., and Lynch K.R. Characterization of a novel sphingosine-1-phosphate receptor, EDG-8. J. Biol. Chem. 275 (2000) 14281-14286
55. 5 receptor. Br. J. Pharmacol. 138 (2003) 481-493
56. Terai K., Soga T., Takahashi M., Kamohara M., Ohno K., Yatsugi S., Okada M., and Yamaguchi T. EDG-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 116 (2003) 1053-1062
57. 5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25 (2005) 1459-1469
58. Yu N., Lariosa-Willingham K.D., Lin F.F., Webb M., and Rao T.S. Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45 (2004) 17-27
59. Kostenis E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands. J. Cell. Biochem. 92 (2004) 923-936
60. Ignatov A., Lintzel J., Hermans-Borgmeyer I., Kreienkamp H.J., Joost P., Thomsen S., Methner A., and Schaller H.C. Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J. Neurosci. 23 (2003) 907-914
61. 2+ release by activating the sphingosine-kinase pathway. Biochem. Biophys. Res. Commun. 311 (2003) 329-336
62. Uhlenbrock K., Huber J., Ardati A., Busch A.E., and Kostenis E. Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells. Cell. Physiol. Biochem.. 13 (2003) 75-84
63. s-linked receptor GPR3 maintains meiotic arrest in mammalian oocytes. Science 306 (2004) 1947-1950
64. Hinckley M., Vaccari S., Horner K., Chen R., and Conti M. The G-protein-coupled receptors GPR3 and GPR12 are involved in cAMP signaling and maintenance of meiotic arrest in rodent oocytes. Dev. Biol. 287 (2005) 249-261
65. Mehlmann L.M. Stops and starts in mammalian oocytes: recent advances in understanding the regulation of meiotic arrest and oocyte maturation. Reproduction 130 (2005) 791-799
66. Ledent C., Demeestere I., Blum D., Petermans J., Hamalainen T., Smits G., and Vassart G. Premature ovarian aging in mice deficient for Gpr3. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8922-8926
67. Morita Y., Perez G.I., Paris F., Miranda S.R., Ehleiter D., Haimovitz-Friedman A., Fuks Z., Xie Z., Reed J.C., Schuchman E.H., Kolesnick R.N., and Tilly J.L. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat. Med. 6 (2000) 1109-1114
68. Spiegel S., and Kolesnick R. Sphingosine 1-phosphate as a therapeutic agent. Leukemia 16 (2002) 1596-1602
69. Xu Y., Zhu K., Hong G., Wu W., Baudhuin L.M., Xiao Y., and Damron D.S. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat. Cell Biol. 2 (2000) 261-267
70. Zhu K., Baudhuin L.M., Hong G., Williams F.S., Cristina K.L., Kabarowski J.H., Witte O.N., and Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J. Biol. Chem. 276 (2001) 41325-41335
71. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., and Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293 (2001) 702-705
72. Im D.S., Heise C.E., Nguyen T., O'Dowd B.F., and Lynch K.R. Identification of a molecular target of psychosine and its role in globoid cell formation. J. Cell Biol. 153 (2001) 429-434
73. Retraction: sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J. Biol. Chem. 280 (2005) 43280
74. Witte O.N., Kabarowski J.H., Xu Y., Le L.Q., and Zhu K. Retraction. Science 307 (2005) 206
75. Bektas M., Barak L.S., Jolly P.S., Liu H., Lynch K.R., Lacana E., Suhr K.B., Milstien S., and Spiegel S. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner. Biochemistry 42 (2003) 12181-12191
76. Ludwig M.G., Vanek M., Guerini D., Gasser J.A., Jones C.E., Junker U., Hofstetter H., Wolf R.M., and Seuwen K. Proton-sensing G-protein-coupled receptors. Nature 425 (2003) 93-98
77. Mogi C., Tomura H., Tobo M., Wang J.Q., Damirin A., Kon J., Komachi M., Hashimoto K., Sato K., and Okajima F. Sphingosylphosphorylcholine antagonizes proton-sensing ovarian cancer G-protein-coupled receptor 1 (OGR1)-mediated inositol phosphate production and cAMP accumulation. J. Pharmacol. Sci. 99 (2005) 160-167
78. Murakami N., Yokomizo T., Okuno T., and Shimizu T. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J. Biol. Chem. 279 (2004) 42484-42491
79. Wang J.Q., Kon J., Mogi C., Tobo M., Damirin A., Sato K., Komachi M., Malchinkhuu E., Murata N., Kimura T., Kuwabara A., Wakamatsu K., Koizumi H., Uede T., Tsujimoto G., Kurose H., Sato T., Harada A., Misawa N., Tomura H., and Okajima F. TDAG8 is a proton-sensing and psychosine-sensitive G-protein-coupled receptor. J. Biol. Chem. 279 (2004) 45626-45633
80. Ishii S., Kihara Y., and Shimizu T. Identification of T cell death-associated gene 8 (TDAG8) as a novel acid sensing G-protein-coupled receptor. J. Biol. Chem. 280 (2005) 9083-9087
81. Radu C.G., Nijagal A., McLaughlin J., Wang L., and Witte O.N. Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1632-1637
82. Kim K.S., Ren J., Jiang Y., Ebrahem Q., Tipps R., Cristina K., Xiao Y.J., Qiao J., Taylor K.L., Lum H., Anand-Apte B., and Xu Y. GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine. FASEB J. 19 (2005) 819-821
83. Qiao J., Huang F., Naikawadi R.P., Kim K.S., Said T., and Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am. J. Physiol., Lung Cell. Mol. Physiol. 291 (2006) L91-L101
84. 2 production and cAMP accumulation in response to acidic extracellular pH through OGR1 in human aortic smooth muscle cells. J. Biol. Chem. 280 (2005) 34458-34464
85. Wang L., Radu C.G., Yang L.V., Bentolila L.A., Riedinger M., and Witte O.N. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol. Biol. Cell 16 (2005) 2234-2247
86. Yang M., Mailhot G., Birnbaum M.J., Mackay C.A., Mason-Savas A., and Odgren P.R. Expression of and role for ovarian cancer G-protein coupled receptor 1 (OGR1) during osteoclastogenesis. J. Biol. Chem. (2006) M602191200
87. Radu C.G., Yang L.V., Riedinger M., Au M., and Witte O.N. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 245-250
88. i-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 105 (2005) 1127-1134
89. Malone M.H., Wang Z., and Distelhorst C.W. The glucocorticoid-induced gene tdag8 encodes a pro-apoptotic G protein-coupled receptor whose activation promotes glucocorticoid-induced apoptosis. J. Biol. Chem. 279 (2004) 52850-52859
90. Le L.Q., Kabarowski J.H., Weng Z., Satterthwaite A.B., Harvill E.T., Jensen E.R., Miller J.F., and Witte O.N. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14 (2001) 561-571
91. Radu C.G., Cheng D., Nijagal A., Riedinger M., McLaughlin J., Yang L.V., Johnson J., and Witte O.N. Normal immune development and glucocorticoid-induced thymocyte apoptosis in mice deficient for the T-cell death-associated gene 8 receptor. Mol. Cell. Biol. 26 (2006) 668-677
92. Spiegel S., and Milstien S. Sphingosine-1-phosphate: signaling inside and out. FEBS Lett. 476 (2000) 55-57
93. McIntyre T.M., Pontsler A.V., Silva A.R., St Hilaire A., Xu Y., Hinshaw J.C., Zimmerman G.A., Hama K., Aoki J., Arai H., and Prestwich G.D. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 131-136
94. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
95. Lee C.H., Olson P., and Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
96. Zhang C., Baker D.L., Yasuda S., Makarova N., Balazs L., Johnson L.R., Marathe G.K., McIntyre T.M., Xu Y., Prestwich G.D., Byun H.S., Bittman R., and Tigyi G. Lysophosphatidic acid induces neointima formation through PPARγ activation. J. Exp. Med. 199 (2004) 763-774
97. Simon M.F., Daviaud D., Pradere J.P., Gres S., Guigne C., Wabitsch M., Chun J., Valet P., and Saulnier-Blache J.S. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor-γ2. J. Biol. Chem. 280 (2005) 14656-14662
98. Simon M.F., Rey A., Castan-Laurel I., Gres S., Sibrac D., Valet P., and Saulnier-Blache J.S. Expression of ectolipid phosphate phosphohydrolases in 3T3F442A preadipocytes and adipocytes. Involvement in the control of lysophosphatidic acid production. J. Biol. Chem. 277 (2002) 23131-23136
99. Saba J.D., and Hla T. Point-counterpoint of sphingosine-1-phosphate metabolism. Circ. Res. 94 (2004) 724-734
100. Hannun Y.A., Luberto C., and Argraves K.M. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 40 (2001) 4893-4903
101. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev., Cancer 4 (2004) 604-616
102. Futerman A.H., and Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15 (2005) 312-318
103. Kohama T., Olivera A., Edsall L., Nagiec M.M., Dickson R., and Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem. 273 (1998) 23722-23728
104. Liu H., Sugiura M., Nava V.E., Edsall L.C., Kono K., Poulton S., Milstien S., Kohama T., and Spiegel S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 275 (2000) 19513-19520
105. Melendez A.J., Carlos-Dias E., Gosink M., Allen J.M., and Takacs L. Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 251 (2000) 19-26
106. Pitson S.M., D'Andrea R.J., Vandeleur L., Moretti P.A.B., Xia P., and Gamble J.R. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem. J. 350 (2000) 429-441
107. Billich A., Bornancin F., Devay P., Mechtcheriakova D., Urtz N., and Baumruker T. Phosphorylation of the imunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. (2003)
108. Okada T., Ding G., Sonoda H., Kajimoto T., Haga Y., Khosrowbeygi A., Gao S., Miwa N., Jahangeer S., and Nakamura S. Involvement of N-terminal-extended form of sphingosine kinase-2 in serum-dependent regulation of cell proliferation and apoptosis. J. Biol. Chem. 280 (2005) 36318-36325
109. Olivera A., and Spiegel S. Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins 64 (2001) 123-134
110. Taha T.A., Hannun Y.A., and Obeid L.M. Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol. 39 (2006) 113-131
111. Wattenberg B.W., Pitson S.M., and Raben D.M. The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J. Lipid Res. 47 (2006) 1128-1139
112. Olivera A., Kohama T., Edsall L., Nava V., Cuvillier O., Poulton S., and Spiegel S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147 (1999) 545-558
113. Xia P., Gamble J.R., Wang L., Pitson S.M., Moretti P.A.B., Wattenberg B.W., D'Andrea R.J., and Vadas M.A. An oncogenic role of sphingosine kinase. Curr. Biol. 10 (2000) 1527-1530
114. Edsall L.C., Cuvillier O., Twitty S., Spiegel S., and Milstien S. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem. 76 (2001) 1573-1584
115. French K.J., Schrecengost R.S., Lee B.D., Zhuang Y., Smith S.N., Eberly J.L., Yun J.K., and Smith C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63 (2003) 5962-5969
116. Bektas M., Jolly P.S., Müller C., Eberle J., Spiegel S., and Geilen C.C. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24 (2005) 178-187
117. Doll F., Pfeilschifter J., and Huwiler A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim. Biophys. Acta 1738 (2005) 72-81
118. Saini H.S., Coelho R.P., Goparaju S.K., Jolly P.S., Maceyka M., Spiegel S., and Sato-Bigbee C. Novel role of sphingosine kinase-1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J. Neurochem. 95 (2005) 1298-1310
119. Pchejetski D., Golzio M., Bonhoure E., Calvet C., Doumerc N., Garcia V., Mazerolles C., Rischmann P., Teissie J., Malavaud B., and Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 65 (2005) 11667-11675
120. Bonhoure E., Pchejetski D., Aouali N., Morjani H., Levade T., Kohama T., and Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20 (2006) 95-102
121. Kawamori T., Osta W., Johnson K.R., Pettus B.J., Bielawski J., Tanaka T., Wargovich M.J., Reddy B.S., Hannun Y.A., Obeid L.M., and Zhou D. Sphingosine kinase-1 is up-regulated in colon carcinogenesis. FASEB J. 20 (2006) 386-388
122. Igarashi N., Okada T., Hayashi S., Fujita T., Jahangeer S., and Nakamura S. Sphingosine kinase-2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 278 (2003) 46832-46839
123. Liu H., Toman R.E., Goparaju S., Maceyka M., Nava V.E., Sankala H., Payne S.G., Bektas M., Ishii I., Chun J., Milstien S., and Spiegel S. Sphingosine kinase type-2 is a putative BH3-Only protein that induces apoptosis. J. Biol. Chem. 278 (2003) 40330-40336
124. Maceyka M., Sankala H., Hait N.C., Le Stunff H., Liu H., Toman R., Collier C., Zhang M., Satin L.S., Merrill Jr. A.H., Milstien S., and Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem. 280 (2005) 37118-37129
125. Allende M.L., Sasaki T., Kawai H., Olivera A., Mi Y., Echten-Deckert G., Hajdu R., Rosenbach M., Keohane C.A., Mandala S., Spiegel S., and Proia R.L. Mice deficient in sphingosine kinase-1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279 (2004) 52487-52492
126. Kharel Y., Lee S., Snyder A.H., Sheasley-O'Neill S.L., Morris M.A., Setiady Y., Zhu R., Zigler M.A., Burcin T.L., Ley K., Tung K.S., Engelhard V.H., Macdonald T.L., Pearson-White S., and Lynch K.R. Sphingosine kinase-2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280 (2005) 36865-36872
127. Mizugishi K., Yamashita T., Olivera A., Miller G.F., Spiegel S., and Proia R.L. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25 (2005) 11113-11121
128. Zemann B., Kinzel B., Müller M., Reuschel R., Mechtcheriakova D., Urtz N., Bornancin F., Baumruker T., and Billich A. Sphingosine kinase type-2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107 (2006) 1454-1458
129. Brindley D.N. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J. Cell. Biochem. 92 (2004) 900-912
130. Pyne S., Kong K.C., and Darroch P.I. Lysophosphatidic acid and sphingosine-1-phosphate biology: the role of lipid phosphate phosphatases. Semin. Cell Dev. Biol. 15 (2004) 491-501
131. Pyne S., Long J.S., Ktistakis N.T., and Pyne N.J. Lipid phosphate phosphatases and lipid phosphate signalling. Biochem. Soc. Trans. 33 (2005) 1370-1374
132. Sigal Y.J., McDermott M.I., and Morris A.J. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem. J. 387 (2005) 281-293
133. Alderton F., Darroch P., Sambi B., McKie A., Ahmed I.S., Pyne N., and Pyne S. G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells. J. Biol. Chem. 276 (2001) 13452-13460
134. Long J., Darroch P., Wan K.F., Kong K.C., Ktistakis N., Pyne N.J., and Pyne S. Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine-1-phosphate pools. Biochem. J. 391 (2005) 25-32
135. Mandala S.M., Thornton R., Galve-Roperh I., Poulton S., Peterson C., Olivera A., Bergstrom J., Kurtz M.B., and Spiegel S. Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1-phosphate and induces cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7859-7864
136. Le Stunff H., Peterson C., Thornton R., Milstien S., Mandala S.M., and Spiegel S. Characterization of murine sphingosine-1-phosphate phosphohydrolase. J. Biol. Chem. 277 (2002) 8920-8927
137. Johnson K.R., Johnson K.Y., Becker K.P., Bielawski J., Mao C., and Obeid L.M. Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J. Biol. Chem. 278 (2003) 34541-34547
138. Ogawa C., Kihara A., Gokoh M., and Igarashi Y. Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2. J. Biol. Chem. 278 (2003) 1268-1272
139. Zhou J., and Saba J.D. Identification of the first mammalian sphingosine phosphate lyase gene and its functional expression in yeast. Biochem. Biophys. Res. Commun. 242 (1998) 502-507
140. van Veldhoven P.P., Gijsbers S., Mannaerts G.P., Vermeesch J.R., and Brys V. Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22. Biochim. Biophys. Acta 1487 (2000) 128-134
141. Ikeda M., Kihara A., and Igarashi Y. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5′-phosphate binding domain exposed to the cytosol. Biochem. Biophys. Res. Commun. 325 (2004) 338-343
142. Reiss U., Oskouian B., Zhou J., Gupta V., Sooriyakumaran P., Kelly S., Wang E., Merrill Jr. A.H., and Saba J.D. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J. Biol. Chem. 279 (2004) 1281-1290
143. Herr D.R., Fyrst H., Phan V., Heinecke K., Georges R., Harris G.L., and Saba J.D. Sply regulation of sphingolipid signaling molecules is essential for Drosophila development. Development 130 (2003) 2443-2453
144. Meyer zu Heringdorf D. Lysophospholipid receptor-dependent and -independent calcium signaling. J. Cell. Biochem. 92 (2004) 937-948
145. Safadi-Chamberlain F., Wang L.P., Payne S.G., Lim C.U., Stratford S., Chavez J.A., Fox M.H., Spiegel S., and Summers S.A. Effect of a membrane-targeted sphingosine kinase-1 on cell proliferation and survival. Biochem. J. 388 (2005) 827-834
146. Johnson K.R., Becker K.P., Facchinetti M.M., Hannun Y.A., and Obeid L.M. PKC-dependent activation of sphingosine kinase-1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J. Biol. Chem. 277 (2002) 35257-35262
147. Pitson S.M., Moretti P.A., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., and Wattenberg B.W. Activation of sphingosine kinase-1 by ERK1/2-mediated phosphorylation. EMBO J. 22 (2003) 5491-5500
148. 2+/calmodulin-dependent translocation of sphingosine kinase: role in plasma membrane relocation but not activation. Cell Calcium 33 (2003) 119-128
149. Toman R.E., Payne S.G., Watterson K.R., Maceyka M., Lee N.H., Milstien S., Bigbee J.W., and Spiegel S. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol. 166 (2004) 381-392
150. 12/13-mediated stress fiber formation yet promotes growth and survival independent of G protein coupled receptors. J. Biol. Chem. 278 (2003) 46452-46460
151. 2+ signals, enzyme release, cytokine production, and chemotaxis. J. Immunol. 173 (2004) 1596-1603
152. Jolly P.S., Bektas M., Watterson K.R., Sankala H., Payne S.G., Milstien S., and Spiegel S. Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood 105 (2005) 4736-4742
153. Hobson J.P., Rosenfeldt H.M., Barak L.S., Olivera A., Poulton S., Caron M.G., Milstien S., and Spiegel S. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291 (2001) 1800-1803
154. Waters C.M., Long J., Gorshkova I., Fujiwara Y., Connell M., Belmonte K.E., Tigyi G., Natarajan V., Pyne S., and Pyne N.J. Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine-1-phosphate receptor-1. FASEB J. 20 (2006) 509-511
155. Waters C.M., Sambi B., Kong K.C., Thompson D., Pitson S.M., Pyne S., and Pyne N.J. Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGFβ receptor-sphingosine-1-phosphate receptor complexes in airway smooth muscle cells. J. Biol. Chem. 278 (2003) 6282-6290
156. Waters C.M., Connell M.C., Pyne S., and Pyne N.J. c-Src is involved in regulating signal transmission from PDGFβ receptor-GPCR(s) complexes in mammalian cells. Cell. Signal. 17 (2005) 263-277
157. Kobayashi N., Nishi T., Hirata T., Kihara A., Sano T., Igarashi Y., and Yamaguchi A. Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J. Lipid Res. 47 (2006) 614-621
158. Ancellin N., Colmont C., Su J., Li Q., Mittereder N., Chae S.S., Stefansson S., Liau G., and Hla T. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J. Biol. Chem. 277 (2002) 6667-6675
159. Venkataraman K., Thangada S., Michaud J., Oo M.L., Ai Y., Lee Y.M., Wu M., Parikh N.S., Khan F., Proia R.L., and Hla T. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem. J. 397 (2006) 461-471
160. Inagaki Y., Li P.Y., Wada A., Mitsutake S., and Igarashi Y. Identification of functional nuclear export sequences in human sphingosine kinase 1. Biochem. Biophys. Res. Commun. 311 (2003) 168-173
161. Schwab S.R., Pereira J.P., Matloubian M., Xu Y., Huang Y., and Cyster J.G. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309 (2005) 1735-1739
162. Hla T. Immunology. Dietary factors and immunological consequences. Science 309 (2005) 1682-1683
163. Bandhuvula P., Tam Y.Y., Oskouian B., and Saba J.D. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J. Biol. Chem. 280 (2005) 33697-33700
164. Tigyi G., and Parrill A.L. Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42 (2003) 498-526
165. Moolenaar W.H., van Meeteren L.A., and Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 26 (2004) 870-881
166. van Meeteren L.A., Ruurs P., Stortelers C., Bouwman P., van Rooijen M.A., Pradere J.P., Pettit T.R., Wakelam M.J., Saulnier-Blache J.S., Mummery C.L., Moolenaar W.H., and Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26 (2006) 5015-5022
167. Tanaka M., Okudaira S., Kishi Y., Ohkawa R., Iseki S., Ota M., Noji S., Yatomi Y., Aoki J., and Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. (2006) M605142200
168. Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K., and Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277 (2002) 39436-39442
169. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., Yamori T., Mills G.B., Inoue K., Aoki J., and Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158 (2002) 227-233
170. Bektas M., Payne S.G., Liu H., Goparaju S., Milstien S., and Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J. Cell Biol. 169 (2005) 801-811
171. Clair T., Aoki J., Koh E., Bandle R.W., Nam S.W., Ptaszynska M.M., Mills G.B., Schiffmann E., Liotta L.A., and Stracke M.L. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63 (2003) 5446-5453
172. Contos J.J., Fukushima N., Weiner J.A., Kaushal D., and Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13384-13389
173. Contos J.J., Ishii I., Fukushima N., Kingsbury M.A., Ye X., Kawamura S., Brown J.H., and Chun J. Characterization of lpa(2) (EDG-4) and lpa(1)/lpa(2) (EDG-2/EDG-4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22 (2002) 6921-6929
174. 3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435 (2005) 104-108
175. Ferry G., Tellier E., Try A., Gres S., Naime I., Simon M.F., Rodriguez M., Boucher J., Tack I., Gesta S., Chomarat P., Dieu M., Raes M., Galizzi J.P., Valet P., Boutin J.A., and Saulnier-Blache J.S. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278 (2003) 18162-18169
176. Boucher J., Quilliot D., Praderes J.P., Simon M.F., Gres S., Guigne C., Prevot D., Ferry G., Boutin J.A., Carpene C., Valet P., and Saulnier-Blache J.S. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48 (2005) 569-577
177. Umemura K., Yamashita N., Yu X., Arima K., Asada T., Makifuchi T., Murayama S., Saito Y., Kanamaru K., Goto Y., Kohsaka S., Kanazawa I., and Kimura H. Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients. Neurosci. Lett. 400 (2006) 97-100
178. Parrill A.L., Wang D., Bautista D.L., Van Brocklyn J.R., Lorincz Z., Fischer D.J., Baker D.L., Liliom K., Spiegel S., and Tigyi G. Identification of EDG-1 receptor residues that recognize sphingosine-1-phosphate. J. Biol. Chem. 275 (2000) 39379-39384
179. 1 (EDG-2) phospholipid growth factor receptors. J. Biol. Chem. 276 (2001) 49213-49220
180. Sardar V.M., Bautista D.L., Fischer D.J., Yokoyama K., Nusser N., Virag T., Wang d.A., Baker D.L., Tigyi G., and Parrill A.L. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim. Biophys. Acta 1582 (2002) 309-317
181. 4 receptor. BMC Biochem. 5 (2004) 12 10.1186/1471-2091-5-12
182. Parrill A.L., Sardar V.M., and Yuan H. Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands, Semin. Cell Dev. Biol. 15 (2004) 467-476
183. Paugh S.W., Cassidy M.P., He H., Milstien S., Sim-Selley L.J., Spiegel S., and Selley D.E. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol. Pharmacol. 70 (2006) 41-50
184. 1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 12 (2005) 703-715
185. Lo C.G., Xu Y., Proia R.L., and Cyster J.G. Cyclical modulation of sphingosine-1-phosphate receptor-1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J. Exp. Med. 201 (2005) 291-301
186. Anselmo D.M., Amersi F.F., Shen X.D., Gao F., Katori M., Lassman C., Ke B., Coito A.J., Ma J., Brinkmann V., Busuttil R.W., Kupiec-Weglinski J.W., and Farmer D.G. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am. J. Transp. 2 (2002) 843-849
187. Troncoso P., Ortiz A.M., Dominguez J., and Kahan B.D. Use of FTY720 and ICAM-1 antisense oligonucleotides for attenuating chronic renal damage secondary to ischemia-reperfusion injury. Transp. Proc. 37 (2005) 4284-4288
188. Awad A.S., Ye H., Huang L., Li L., Foss Jr. F.W., Macdonald T.L., Lynch K.R., and Okusada M.D. Selective sphingosine-1-phosphate-1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol.: Renal, Physiol. 290 (2006) F1516-F1524
189. 1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. 69 (2006) 1601-1608
190. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., Probst B., Butler J., Wood A., Liau G., Billy E., Theuer A., Hla T., and Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66 (2006) 221-231
191. 1 antagonist in vivo. Nat. Chem. Biol. 2 (2006) 434-441
192. 3. Circ. Res. 96 (2005) 913-920
193. Sanchez T., Estrada-Hernandez T., Paik J.H., Wu M.T., Venkataraman K., Brinkmann V., Claffey K., and Hla T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278 (2003) 47281-47290
194. Koide Y., Hasegawa T., Takahashi A., Endo A., Mochizuki N., Nakagawa M., and Nishida A. Development of novel EDG-3 antagonists using a 3D database search and their structure-activity relationships. J. Med. Chem. 45 (2002) 4629-4638
195. Osada M., Yatomi Y., Ohmori T., Ikeda H., and Ozaki Y. Enhancement of sphingosine-1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem. Biophys. Res. Commun. 299 (2002) 483-487
196. 2. Cardiovasc. Res. 58 (2003) 170-177
197. Davis M.D., Clemens J.J., Macdonald T.L., and Lynch K.R. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280 (2005) 9833-9841
198. 2 receptor. Biochem. Biophys. Res. Commun. 346 (2006) 293-300
199. van Schooten B., Testerink C., and Munnik T. Signalling diacylglycerol pyrophosphate, a new phosphatidic acid metabolite. Biochim. Biophys. Acta 1761 (2006) 151-159
200. Fischer D.J., Nusser N., Virag T., Yokoyama K., Wang D., Baker D.L., Bautista D., Parrill A.L., and Tigyi G. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 60 (2001) 776-784
201. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., Kimura T., Tobo M., Yamazaki Y., Watanabe T., Yagi M., Sato M., Suzuki R., Murooka H., Sakai T., Nishitoba T., Im D.S., Nochi H., Tamoto K., Tomura H., and Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64 (2003) 994-1005
202. Rother E., Brandl R., Baker D.L., Goyal P., Gebhard H., Tigyi G., and Siess W. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108 (2003) 741-747
203. Virag T., Elrod D.B., Liliom K., Sardar V.M., Parrill A.L., Yokoyama K., Durgam G., Deng W., Miller D.D., and Tigyi G. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 63 (2003) 1032-1042
204. 3 receptor antagonist. Mol. Pharmacol. 60 (2001) 1173-1180
205. 3 receptor. J. Biol. Chem. 278 (2003) 11962-11969
206. 3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol.: Renal, Physiol. 285 (2003) F565-F574
207. Prestwich G.D., Xu Y., Qian L., Gajewiak J., and Jiang G. New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors. Biochem. Soc. Trans. 33 (2005) 1357-1361
208. Visentin B., Vekich J.A., Sibbald B.J., Cavalli A.L., Moreno K.M., Matteo R.G., Garland W.A., Lu Y., Yu S., Hall H.S., Kundra V., Mills G.B., and Sabbadini R.A. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9 (2006) 225-238
209. Milstien S., and Spiegel S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 9 (2006) 148-150
210. French K.J., Upson J.J., Keller S.N., Zhuang Y., Yun J.K., and Smith C.D. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther. 318 (2006) 596-603
211. Goetzl E.J., and Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J. Clin. Invest. 114 (2004) 1531-1537
212. Kee T.H., Vit P., and Melendez A.J. Sphingosine kinase signalling in immune cells. Clin. Exp. Pharmacol. Physiol. 32 (2005) 153-161
213. Olivera A., and Rivera J. Sphingolipids and the balancing of immune cell function: lessons from the mast cell. J. Immunol. 174 (2005) 1153-1158
214. Lin D.A., and Boyce J.A. Lysophospholipids as mediators of immunity. Adv. Immunol. 89 (2006) 141-167
215. Alewijnse A.E., Peters S.L., and Michel M.C. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br. J. Pharmacol. 143 (2004) 666-684
216. Siess W., and Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J. Cell. Biochem. 92 (2004) 1086-1094
217. 3 receptors. Drug News Perspect. 17 (2004) 365-382
218. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 15 (2005) 265-271
219. McVerry B.J., and Garcia J.G. In vitro and in vivo modulation of vascular barrier integrity by sphingosine-1-phosphate: mechanistic insights. Cell. Signal. 17 (2005) 131-139
220. Watterson K.R., Ratz P.H., and Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell. Signal. 17 (2005) 289-298
221. Brinkmann V., and Baumruker T. Pulmonary and vascular pharmacology of sphingosine-1-phosphate. Curr. Opin. Pharmacol. 6 (2006) 244-250
222. Yatomi Y. Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr. Pharm. Des. 12 (2006) 575-587
223. Toman R.E., and Spiegel S. Lysophospholipid receptors in the nervous system. Neurochem. Res. 27 (2002) 619-627
224. Chun J. Lysophospholipids in the nervous system. Prostaglandins Other Lipid Mediators 77 (2005) 46-51
225. Padron J.M. Sphingolipids in anticancer therapy. Curr. Med. Chem. 13 (2006) 755-770
226. Tigyi G. Selective ligands for lysophosphatidic acid receptor subtypes: gaining control over the endothelial differentiation gene family. Mol. Pharmacol. 60 (2001) 1161-1164
227. Sin W.C., Zhang Y., Zhong W., Adhikarakunnathu S., Powers S., Hoey T., An S., and Yang J. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene 23 (2004) 6299-6303
228. Delon C., Manifava M., Wood E., Thompson D., Krugmann S., Pyne S., and Ktistakis N.T. Sphingosine kinase-1 is an intracellular effector of phosphatidic acid. J. Biol. Chem. 279 (2004) 44763-44774